One-year incidence of hospital readmission in hematopoietic cell transplant recipients and reasons for readmissions

Yi-Chien Lee,1 MS; Essy Mozaffari,2 PharmD, MPH, MBA; Vernon F. Schabert,1 PhD; Vishal Patel,1 BSc; Roman Casciano,1 MSc

1LASER Analytica, New York, NY, USA; 2Chimerix, Durham, NC, USA

INTRODUCTION

Hematopoietic cell transplantation (HCT) is a potentially curative therapy for patients with certain high-risk hematologic diseases.1

Complications from graft-vs-host disease (GVHD) and immunosuppression result in significant hospital readmission risks for patients following HCT.2

In this study we describe the readmission rates, and reasons for readmission, among HCT recipients during the first year following the HCT procedure.

RESULTS

Patient population

Table 1 details the baseline characteristics of the study population, which consisted of 2926 allogeneic HCT and 4761 autologous HCT recipients.3

The mean age of the allogeneic and autologous HCT recipients was 47.3 years and 53.4 years, respectively.4

1662 of 2926 (56.0%) of allogeneic HCT recipients and 2855 of 4761 (60.0%) autologous HCT recipients were male.5

Total healthcare expenditure for each patient was calculated during the 365 days prior to the transplant procedure as an indicator of disease severity.

Mean (median) total healthcare reimbursements were $3,071 ($1,961) for allogeneic HCT recipients and $17,763 ($12,395) for autologous HCT recipients during the 365 days prior to the transplant.

DISCUSSION

Readmissions for adult and pediatric populations

Figures 1 and 2 show readmissions among adult and pediatric populations who underwent allogeneic and autologous HCT transplants.6

Limited differences were observed between adult and pediatric recipients including allogeneic HCT transplants.

Adulthood appeared to be slightly more likely to be readmitted for GVHD and renal impairment.7

The findings were similar for autologous HCT recipients: in addition to infections, there was evidence that adults had more hospitalizations associated with opportunistic infections.

LIMITATIONS

A limitation of our study is potential underreporting of ICD-9 diagnosis codes; thus, the number of readmissions for each reason may be underestimated.

REFERENCES

4.Essy Mozaffari, Roman Casciano, and Yi-Chien Lee have served as a consultant or received compensation from Chimerix, Inc.
5.Essy Mozaffari is an employee of Chimerix and has been granted stock and stock options.

ACKNOWLEDGMENTS

Editorial assistance was provided by Katrina Rimmer, at Caudles Medical (Cork, UK), funded by Chimerix.